SPA
SPRY icon

Sherbrooke Park Advisers’s ARS Pharmaceuticals SPRY Stock Holding History

Sherbrooke Park Advisers’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$153K Buy
+13,139
New +$128K 0.4% 105

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sherbrooke Park Advisers's SPRY Position: Q4 2025 in Review

Sherbrooke Park Advisers opened a new position in ARS Pharmaceuticals (SPRY) in Q4 2025: 13,139 shares worth $153K. The stake represents 0.4% of the portfolio and ranks #105 among its holdings.

189 funds tracked by Wall St. Rank hold SPRY as of Q4 2025.

  • Sherbrooke Park Advisers held 13,139 shares of ARS Pharmaceuticals worth $153K as of Q4 2025.
  • ARS Pharmaceuticals was a new Sherbrooke Park Advisers position in Q4 2025.
  • ARS Pharmaceuticals made up 0.4% of Sherbrooke Park Advisers's portfolio in Q4 2025, its #105 holding.
  • 189 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.